LATANOPROST
| Brand name | XELPROS |
|---|---|
| Active ingredient | LATANOPROST |
| Strength | 0.005% |
| Dosage form | EMULSION |
| Route | OPHTHALMIC |
| Modality | Small molecule |
| FDA approval | September 2018 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 9629852 | September 2029 | product |
| 9539262 | October 2028 | use U-2400 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.